东莨菪碱联合前列腺素E_1治疗肺心病并呼吸衰竭的临床研究

The Clinical Study of Scopolamine Combined with Prostaglandin E_1 Treatment of Pulmonary heart disease with Respiratory Failure

目的探讨东莨菪碱联合前列腺素E1治疗肺心病并呼吸衰竭的疗效。方法对72例肺心病并呼吸衰竭患者,随机分为2组,对照组37例,治疗组36例,治疗组在常规治疗基础上,应用东莨菪碱联合前列腺素E1,并对其结果进行分析。结果治疗组3例,总有效率85.7%,对照组37例,总有效率45.9%,两组有效率有显著性差异(P<0.01)。两组治疗1周后PaO2、PaCO2和SaO2与对照组相比均有显著性差异(P<0.01)。结论应用东莨菪碱联合前列腺素E1治疗肺心病并呼吸衰竭有显著疗效。

Objective To explore the carative effects of scopolamine combined with prostaglandin E1 in treatment of pulmonary heart disease with respiratory failure. Methods 72 cases were randomly divided into control group （37 casess） with routine therapy and experimental group （35 cases） with scopolamine combined with prostaglandin E1 based on routine treatment. The to evaluate the results. Results The rate of effect was 85.7% in experimental group and 45.9% in the control group, there was a significant difference in statitics （ P 〈0. 01 ）. The experimental group＇ s PaO2 and SaO2 in post-treatment one wkke were significantly higher than in the control group （ P 〈0. 01 ）. Conclusions Scopolamine combined with prostagiandin E1 was obviously effective in the treatment of pulmonary heart disease with respiratory failure.